Efficacy and safety of treatment with Azilsartan in type 2 diabetes mellitus patients with hypertension who did not show target blood pressure by telmisartan.

Efficacy and safety of treatment with Azilsartan in type 2 diabetes mellitus patients with hypertension who did not show target blood pressure by telmisartan. - Study of Switching to Azilsartan from Telmisartan in type 2 diabetes mellitus patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010604

Enrollment

Registered

2013-05-01

Start date

2013-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus with hypertension

Interventions

switching to Azilsartan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients with type 2 diabetes mellitus with hypertension vistited our Hospital and approved with this study. They who were being treated with telmisartan 40mg at least for 8 weeks did not reached aim of decrease of blood pressure. Medication other than antihypertensive drug was not changed for 8weeks.

Exclusion criteria

Exclusion criteria: 1)patients who wrere poorly controlled . 2)patients with secondary hypertension. 3)patients on HD. 4)pregnant patients. 5)patients who wrere allergic to telmisartan. 6)patients with heavy liver dysfunction. 7)patients with heavy renal dysfunction(Cre>3mg/dL).

Design outcomes

Primary

Measure	Time frame
blood pressure and HbA1c at 0, 4, 8, and 12 weeks after starting of treatment	—

Secondary

Measure	Time frame
AST, ALT, gamma-GTP, LDL, HDL, TG, fasting glucose, adiponectin, safty at 0, 4, 8, and 12 weeks after starting of treatment	—

Countries

Japan

Contacts

Public ContactSatoko Ono

Iwasaki Naika Clinic Internal medicien

toiwasaki-dm@umin.ac.jp045-442-6475

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026